Three more domestic vaccines are ready for first human trials in China, including two mRNA vaccines. Phase 1 testing will determine whether the substances are harmless and have a quantifiable effect. A Chinese vaccine that could perform well against Omicron and other new variants would be the way out of a potential series of lockdowns. Therefore, China is pushing ahead with research on alternatives to its only moderately effective dead vaccines. Candidate vaccines from the following suppliers are now entering the testing phase:
Continue reading now
Get 30 days of free access to the Decision Brief to read these and more quality news every day.
Are you already a guest at the China.Table? Log in now